BBC News
BBC News
A lung cancer therapy can more than double life expectancy in some patients, a "milestone" trial shows. Nivolumab stops cancerous cells hiding from the body's own defences, leaving the cancer vulnerable to attack. The results from 582 people, presented at ...
More cancer success with drugs that enlist immune system New Zealand Herald
New immunotherapy drug outperforms chemotherapy for a form of lung cancer Washington Post
Bristol's Opdivo reduces risk of death from common lung cancer Reuters
Forbes -Philly.com -Bloomberg
all 139 news articles »
from @ Health and Medical News http://ift.tt/1G9ml68
via Health and Medical NewsHealth and Medical News Pfizer Inc has already had its takeover overtures rebuffed three times by rival AstraZeneca Plc, but investors in the U.S. drugmaker say it can tolerate a little more rejection before going hostile with the deal. AstraZeneca turned down a sweeten...
